dagamma ecommerce solutions

Cloud DX and Dagamma Team Up to Reduce the Risk of Maternal Hypertension

Cloud DX and Dagamma Team Up to Reduce the Risk of Maternal Hypertension

News in summary

  • Cloud DX signs new revenue sharing channel partnership agreement with Dagamma
  • Joint solution will help expectant mothers detect hypertension during pregnancy
  • Market is the 10% of pregnancies wherein women suffer from high blood pressure
  • Hypertension remains a leading cause for maternal and perinatal mortality
  • Dagamma eCommerce channels see 70K unique visitors/m and >10K transactions/m

Cloud DX (TSXV:CDX)(OTCQB:CDXFF), a leading North American provider of virtual care and remote patient-monitoring solutions, is pleased to announce a new commercial agreement with Dagamma Ecommerce Solutions (‘Dagamma'). As a niche market leader in the US market, Dagamma delivers innovative consumer wellness and tracking solutions for growing families. The arrangement brings Cloud DX's award-winning Connected Health remote patient-monitoring solution to expectant mothers at risk for maternal hypertension

Hypertensive disorders of pregnancy (HDPs), chronic (or pre-existing) hypertension, gestational hypertension and, especially, pre-eclampsia, remain leading causes of maternal and perinatal morbidity and mortality. Risk factors include a mother's age being over 35, a history of migraines, existing hypertension, and auto-immune diseases. According to Cleveland Clinic, high blood pressure complicates about 10% of pregnancies.

Cloud DX Connected Health has been deployed by leading ob-gyns to manage maternal blood pressure in office and clinical settings since 2017.

Under the newly signed agreement, Dagamma will market a Cloud DX-branded, guided self-care maternal blood pressure program to purchasers via its established distribution channels, including its main website babydoppler.com and retail/eCommerce partners including Amazon, Walmart, Target and BestBuy. Cloud DX and Dagamma will share revenues.

The program includes a Cloud DX integrated wireless blood pressure cuff and Connected Health app along with educational materials, coaching support from Cloud DX staff and approximately five months of automated monitoring covering pre- and post-delivery periods. If the Cloud DX remote automated monitoring software detects a trend towards elevated blood pressure, the user is notified and can print or save a report of her vital signs to forward to her physician. Cloud DX will not supply medical services or advice through this program. Sales of Cloud DX programs with Dagamma are expected to begin on or before September 1, 2021.

"Cloud DX Connected Health has given me extreme confidence in accurately diagnosing significant changes in blood pressure, particularly in high-risk pregnancies," says Dr. Sandy Sharma, an obstetrician in Oakville, ON who has used Cloud DX hypertension management with patients in his clinical practice.

Dagamma's online eCommerce portal babydoppler.com receives an average of 70,000 unique visitors per month and processes more than 10,000 transactions per month.

"This new distribution partnership dramatically scales up Cloud DX's ability to improve outcomes for Connected Health end-users. With more than 120,000 completed transactions per year through Dagamma's combined channels in the US there is clearly strong demand for at-home tools to improve maternal health," says Cloud DX CEO Robert Kaul. "Our mission is to make healthcare better for everyone, and this new relationship meets that goal head on."

Cloud DX will be hosting its second quarter investor update and earnings call on August 17, 2021, at 1:30 pm EST. To register please use the link below:
Cloud DX Webinar Link

About Cloud DX
Accelerating virtual healthcare's future, Cloud DX is making healthcare better for everyone. The company's Connected Health remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable ageing in place and deliver hospital-quality post-surgical care. Providers partnering with Cloud DX achieve better healthcare and patient outcomes, reduce the need for hospitalization, re-hospitalization and ER visits and reduce the costs of healthcare delivery through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company 'World Changing Idea' finalist and one of 'Canada's Ten Most Prominent Telehealth Providers.'

About Dagamma
Dagamma Ecommerce Solutions Inc. creates and operates top quality ecommerce platforms that distribute thoughtfully designed consumer products around the needs of new/expecting moms and babies. As a niche market leader in the US, the company delivers innovative consumer wellness + tracking solutions for growing families and are expanding across the category to create a one-stop destination for our valued customers. The company's flagship product, Sonoline B is the most accurate fetal doppler device on the market today and is widely used by ob-gyns as well as by mothers at home.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Social Links
Twitter: https://twitter.com/CloudDX
Facebook https://www.facebook.com/clouddxinc/
LinkedIn https://www.linkedin.com/company/cloud-dx/
Instagram https://www.instagram.com/cloud.dx/

For media inquiries please contact:
Ellyn Winters-Robinson
Ignition Communications (PR for Cloud DX)
519-574-2196
ellyn@ignition.ca

For Dagamma inquiries please contact:
Jessie Ju
Chief Financial Officer
647-991-4111
jessie.ju@dagamma.com

For investor inquiries please contact:
Jay Bedard
Cloud DX Investor Relations
647-881-8418
jay.bedard@clouddx.com
https://zoom.us/webinar/register/WN_aoM3X1mORRmEUTNpQ32RHQ

SOURCE: Cloud DX Inc.



View source version on accesswire.com:
https://www.accesswire.com/659010/Cloud-DX-and-Dagamma-Team-Up-to-Reduce-the-Risk-of-Maternal-Hypertension

News Provided by ACCESSWIRE via QuoteMedia

The Conversation (0)
Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ("CT26"), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.

In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is pleased to announce the establishment of its new Advisory Board. The Advisory Board will collaborate with management and the board of directors to enhance the Company's strategic direction, provide expert guidance on its commercial initiatives, offer industry insights, and shape and accelerate innovations.

As the inaugural member of the Advisory Board, Syntheia welcomes Mr. John Kirk, a leader in the travel industry. The travel sector represents a potentially significant growth market for the Company's technology.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is transforming customer service by delivering an innovative solution that uses natural language processing (NLP) to handle inbound telephone calls with virtual assistants. Since its beta launch in June 2023, Syntheia has processed over 750,000 conversations, bringing new levels of efficiency and engagement to businesses in diverse industries.

Companies like Georgetown Hyundai, Palmieri Furniture, Campio Furniture, and Pay N Go have all embraced Syntheia's platform, highlighting its positive impact on sales and customer satisfaction.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies Inc.  Opens the Market

Zero Candida Technologies Inc. Opens the Market

Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.

Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.

Please refer to the Company's website here.

MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
victoria@zero-candida.com
416-706-0332

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
XReality Group

xReality Group Limited Chairman’s Address 2024 Annual General Meeting – 22 November 2024

xReality Group Limited (ASX:XRG) (xReality) is pleased to present xReality Group Limited’s 2024 Annual General Meeting.

Keep reading...Show less
XReality Group

Operator XR – Sales Update November 24

xReality Group Limited (ASX:XRG) (xReality) is pleased to provide the following sales update for Operator XR, a wholly owned subsidiary of xReality Group Ltd. Operator XR provides Military and Law Enforcement agencies around the world with a unique, integrated Mission Planning & Rehearsal System, which is portable, secure, and highly immersive.

Keep reading...Show less

Latest Press Releases

Related News

×